Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying ...

Others, however, may have multiple affected joints, have skin and other symptoms, and experience a more severe disease course. But thanks to advances in PsA treatments, most disease complications can ...

Psoriatic arthritis treatments can vary depending on the range and severity of symptoms that you may experience. When people with psoriatic arthritis begin to experience moderate or severe symptoms ...

A sudden onset of symptoms is called a flare. Talk to your primary care doctor and get a referral to a rheumatologist or dermatologist, who specialize in psoriasis and PsA. A rheumatologist or ...

Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised questions about whether the tyrosine kinase 2 (TYK2) inhibitor ...

(RTTNews) - Drug maker Bristol-Myers Squibb Co. (BMY) Monday announced positive topline results from two pivotal Phase 3 trials evaluating Sotyktu (deucravacitinib) in adults with active psoriatic ...

Differences in how men and women manifest and experience psoriatic arthritis suggest it’s time to think of patient sex as a biomarker, one researcher said.

Psoriatic arthritis (PsA) most often attacks and damages ... The more severe your PsA symptoms, the more likely you will have gum inflammation. Dental implants are part of the treatment for ...

Long-term treatment with guselkumab is associated with sustained improvements in joint/skin symptoms and disease activity among patients with active PsA.

The good news is that there do appeared to be proteins which clearly distinguish psoriasis from psoriatic arthritis, and ...

Bristol Myers on Monday said the two Phase 3 studies met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving at least a 20% improvement in signs and ...

A research team from the University of Central Florida's College of Medicine conducted a study of patient perceptions of ...